ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
고셔병 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.6%로 성장할 전망이며, 22억 1,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 차세대 치료, 전 세계 환자 등록 확대, 치료 접근성 개선, 개별화 의료 접근법, 희귀 질환에 대한 규제 지원 등에 기인할 것으로 보입니다. 예측 기간 세계 동향에는 치료 모니터링에 있어서 기술 혁신, 연구에 있어서 국제 협력, 경구 치료약의 진보, 신생아 스크리닝 프로그램 확대, 환자 접근을 위한 세계적 협력 등이 포함됩니다.
유전자이상 유병률 증가는 향후 몇 년간의 고셔병 시장의 성장을 견인할 것으로 예상됩니다. 유전자 이상이란 개인 유전자의 DNA 배열에 변화나 변이가 생기고 그것이 비정상적인 특징이나 기능, 특성으로 이어지는 것을 말합니다. 고셔병은 상염색체 열성 유전이기 때문에 발병하려면 변이된 GBA 유전자를 부모로부터 2개씩 물려받아야 합니다. 고셔병을 가진 사람은 특정 효소가 충분히 생산되지 않기 때문에 비장이나 간 등의 특정 장기에 지질로 알려진 지방 물질이 축적됩니다. 예를 들면, 미국을 거점으로 하는 비영리단체 Cystic Fibrosis Foundation은 2023년 폐이식을 하지 않는 낭포성 섬유증의 총인구는 2022년에 31,171명이었으나 2023년에는 31,752명으로 증가했다고 보고하고 있습니다. 이처럼 유전자 이상 유병률의 증가가 고셔병 시장의 성장에 박차를 가하고 있습니다.
고셔병 시장의 성장은 임상시험 수 증가에 의해 촉진될 것으로 예상됩니다. 임상시험은 인간이 참여하여 새로운 치료, 개입, 약제의 안전성과 유효성을 평가하는 것입니다. 고셔병의 임상시험 증가는 치료의 진보, 질환 이해의 향상, 진단과 스크리닝의 개선, 개별화 의료의 개발로 이어질 가능성이 있습니다. 2023년 5월 엑스톡스에 따르면 452,604건의 임상시험이 등록되어 있고 64,838건이 적극적으로 참가자를 구하고 있습니다. 이는 2021년 등록시험 수 365,000건에서 크게 증가하고 있으며, 고셔병 시장 성장에 크게 기여하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 고셔병 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 고셔병 시장 : 성장률 분석
세계의 고셔병 시장 실적 : 규모 및 성장(2019-2024년)
세계의 고셔병 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 고셔병 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 고셔병 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
고셔병 1형
고셔병 2형
고셔병 3형
기타 유형
세계의 고셔병 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
신체 검사
혈액 검사
화상 검사
임신 전 스크리닝 및 출생 전 검사
기타 진단
세계의 고셔병 시장 : 테라피별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 보충 요법
기질 감소 요법
세계의 고셔병 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
비경구
기타 투여 경로
세계의 고셔병 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
홈케어
기타 최종 사용자
세계의 고셔병 시장 : 고셔병 1형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 보충 요법(ERT)
기질 감소 요법(SRT)
세계의 고셔병 시장 : 고셔병 2형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
지지 요법
실험적 치료법
세계의 고셔병 시장 : 고셔병 3형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 보충 요법(ERT)
증상 관리
세계의 고셔병 시장 : 기타 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
고셔병의 드문 돌연변이
관련 증후군
제7장 지역별 및 국가별 분석
세계의 고셔병 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 고셔병 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
고셔병 시장 : 경쟁 구도
고셔병 시장 : 기업 프로파일
Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
Merck and Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Abbott Laboratories
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Moderna Inc.
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
BioMarin Pharmaceutical Inc.
CHIESI Farmaceutici SPA
IntraBio Inc.
REGENXBIO Inc.
JCR Pharmaceuticals Co. Ltd.
Ultragenyx Pharmaceutical Inc.
Amicus Therapeutics Inc.
Pharming Group NV
Idorsia Pharmaceuticals Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
고셔병 시장 : 새로운 기회를 제공하는 국가(2029년)
고셔병 시장 : 새로운 기회를 제공하는 부문(2029년)
고셔병 시장 : 성장 전략(2029년)
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Gaucher's disease, a rare genetic disorder, disrupts the metabolism of a specific type of fat known as glucocerebroside. The disorder arises from the accumulation of a fatty substance called glucocerebroside within certain cells, particularly in the spleen, liver, bone marrow, and sometimes in the brain.
The primary categories of Gaucher's disease encompass Gaucher disease type 1, Gaucher disease type 2, Gaucher disease type 3, and others. Gaucher disease type 1, the most prevalent form, is distinguished by a deficiency of the enzyme glucocerebrosidase. The diverse diagnostic methods include physical examinations, blood tests, imaging tests, preconception screening, prenatal testing, and others. Treatment options involve enzyme replacement therapy and substrate reduction therapy, which can be administered through oral, parenteral, and various other routes by end users such as hospitals, specialty clinics, homecare, and others.
The Gaucher's disease market research report is one of a series of new reports from The Business Research Company that provides Gaucher's disease market statistics, including the Gaucher's disease industry global market size, regional shares, competitors with Gaucher's disease market share, detailed Gaucher's disease market segments, market trends and opportunities, and any further data you may need to thrive in the Gaucher's disease industry. This Gaucher's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gaucher's disease market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to enzyme replacement therapy (ert) development, increasing disease awareness, genetic research and diagnosis, patient advocacy initiatives, government incentives for rare diseases.
The gaucher's disease market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to next-generation therapies, global patient registry expansion, improvements in access to treatment, personalized medicine approaches, regulatory support for rare diseases. Major trends in the forecast period include technological innovations in treatment monitoring, international collaborations in research, oral therapeutics advancements, expanded newborn screening programs, global collaboration for patient access.
The increasing prevalence of genetic abnormalities is anticipated to drive the growth of the Gaucher's disease market in the coming years. Genetic abnormalities refer to changes or mutations in the DNA sequence of an individual's genes that can lead to abnormal features, functions, or characteristics. Gaucher's disease follows an autosomal recessive inheritance pattern, meaning that a person must inherit two copies of the mutated GBA gene, one from each parent, to develop the condition. Individuals with Gaucher's disease do not produce enough of a specific enzyme, resulting in the accumulation of fatty substances known as lipids in certain organs, such as the spleen and liver. For example, in 2023, the Cystic Fibrosis Foundation, a US-based non-profit organization, reported that the total population with cystic fibrosis without lung transplants was 31,171 in 2022 and rose to 31,752 in 2023. Thus, the increasing prevalence of genetic abnormalities is fueling the growth of the Gaucher's disease market.
The growth of the Gaucher's disease market is expected to be fueled by the rising number of clinical trials. Clinical trials, involving human participants, evaluate the safety and efficacy of new medical treatments, interventions, or drugs. Increased clinical trials in Gaucher's disease can lead to advancements in treatment, better disease understanding, improved diagnosis and screening, and the potential development of personalized medicine. According to Xtalks in May 2023, there are 452,604 registered clinical studies, with 64,838 actively seeking participants. This marks a substantial increase from the 365,000 registered trials in 2021, contributing significantly to the growth of the Gaucher's disease market.
Major companies in the Gaucher's disease market are adopting innovative technologies such as next-generation sequencing (NGS) to enhance patient care. NGS, a high-throughput sequencing technology, enables rapid and cost-effective DNA and RNA sequencing. For instance, Eurofins Genomics LLC launched a whole plasmid sequencing service utilizing advanced Gen3 NGS technology, offering same-day results with up to 99% single-base accuracy. This service, accommodating DNA constructs from 2.5 to 300 kb, combines the accuracy and quick turnaround of Sanger sequencing with NGS's comprehensive analysis capabilities, providing a cost-effective and time-efficient solution for genetic analysis.
Key companies in the Gaucher disease market are concentrating on developing innovative solutions such as AAV gene therapy, aimed at providing a groundbreaking, one-time treatment for Gaucher disease Type 1. Adeno-associated virus (AAV) gene therapy utilizes AAV vectors to deliver therapeutic genes to cells, thereby correcting disease-causing mutations. For example, in January 2022, Freeline Therapeutics Holdings plc, a UK-based biotechnology firm, announced that the US FDA approved FLT201 for Gaucher disease Type 1. FLT201 employs an advanced AAVS3 capsid paired with a liver-specific promoter to deliver a novel glucocerebrosidase variant (GCasevar85). This FDA-cleared IND represents the first AAV-mediated gene therapy to enter clinical trials for Gaucher disease Type 1, underscoring its potential to provide a new therapeutic option for patients.
Major companies operating in the gaucher's disease market report are Pfizer Inc., Johnson & Johnson, Merck and Co. Inc., Novartis AG, Sanofi S.A., Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Moderna Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, BioMarin Pharmaceutical Inc., CHIESI Farmaceutici SPA, IntraBio Inc., REGENXBIO Inc., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Pharming Group N.V., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, AVROBIO Inc., Resverlogix Corp., GenSight Biologics S.A., ISU Abxis Co. Ltd., SIRION BIOTECH GmbH, Greenovation Biotech GmbH, Orphazyme A/S
North America was the largest region in the Gaucher's disease market in 2024. Europe is expected to be the fastest growing region in the forecast period. The regions covered in the gaucher's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the gaucher's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The gaucher's disease market includes revenues earned by entities by providing services such as genetic counseling, patient education and support, research and clinical trials, and pain management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The gaucher's disease market consists of sales of bone health supplements, medical equipment, and diagnostic testing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gaucher's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gaucher's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gaucher's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gaucher's disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Gaucher Disease Type 1; Gaucher Disease Type 2; Gaucher Disease Type 3; Other Types
2) By Diagnosis: Physical Exam; Blood Tests; Imaging Tests; Preconception Screening And Prenatal Testing; Other Diagnoses
3) By Therapy: Enzyme Replacement Therapy; Substrate Reduction Therapy
4) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
5) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Gaucher Disease Type 1: Enzyme Replacement Therapy (ERT); Substrate Reduction Therapy (SRT)
2) By Gaucher Disease Type 2: Supportive Care; Experimental Therapies
3) By Gaucher Disease Type 3: Enzyme Replacement Therapy (ERT); Symptomatic Management
4) By Other Types: Rare Variants Of Gaucher Disease; Related Syndromes
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck and Co. Inc.; Novartis AG; Sanofi S.A.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gaucher's Disease Market Characteristics
3. Gaucher's Disease Market Trends And Strategies
4. Gaucher's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Gaucher's Disease Growth Analysis And Strategic Analysis Framework
5.1. Global Gaucher's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gaucher's Disease Market Growth Rate Analysis
5.4. Global Gaucher's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gaucher's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gaucher's Disease Total Addressable Market (TAM)
6. Gaucher's Disease Market Segmentation
6.1. Global Gaucher's Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gaucher Disease Type 1
Gaucher Disease Type 2
Gaucher Disease Type 3
Other Types
6.2. Global Gaucher's Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Physical Exam
Blood Tests
Imaging Tests
Preconception Screening And Prenatal Testing
Other Diagnoses
6.3. Global Gaucher's Disease Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy
Substrate Reduction Therapy
6.4. Global Gaucher's Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.5. Global Gaucher's Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End Users
6.6. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy (ERT)
Substrate Reduction Therapy (SRT)
6.7. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Supportive Care
Experimental Therapies
6.8. Global Gaucher's Disease Market, Sub-Segmentation Of Gaucher Disease Type 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy (ERT)
Symptomatic Management
6.9. Global Gaucher's Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rare Variants Of Gaucher Disease
Related Syndromes
7. Gaucher's Disease Market Regional And Country Analysis
7.1. Global Gaucher's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gaucher's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
